March 30, 2009 (FinancialWire) -- Immunotech Laboratories, Inc. (OTC: IMMB) has completed a reverse merger with a public shell company and has restructured its position through a 100 to 1 reverse split of stock.

The company has issued 60 million authorized shares bringing its total number of issued and outstanding shares to 60,555,688 shares.

Glendale, California-based Immunotech Laboratories aims to develop novel therapeutic molecules for the treatment of HIV/AIDS and a research pipeline with potential treatments for pre-natal and pediatric HIV/AIDS patients, subsequently developing a Preventive HIV Vaccine.

Immunotech has indefinite licensing rights of the Irreversible Pepsin Fraction peptide molecule for the specific treatment of the HIV/AIDS indication.

The U.S. Patent office has granted full patent rights for IPF under patent number 7479538. The company is in preparation to initiate efforts of acquiring fast track status designation from the FDA.

FinancialWire" ( http://www.financialwire.net ), an independent, proprietary news service of Investrend Communications, Inc., receives no compensation for its news or opinions. Further disclosure is at http://www.investrend.com/articles/secondlevel.asp?level=472 . To contact FinancialWire" write to inquiries@financialwire.net .

Free annual reports for companies mentioned in the news are accessible via http://investrend.ar.wilink.com/?level=279 .

Copyright(C)2009 by financialwire.net, Inc. All rights reserved.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.